Stockscreener 앱 받기
18.91
0.73%
-0.14
전일 마감가:
$19.05
열려 있는:
$18.8
하루 거래량:
2.48M
Relative Volume:
0.81
시가총액:
$60.39B
수익:
$29.91B
순이익/손실:
$1.30B
주가수익비율:
46.62
EPS:
0.4056
순현금흐름:
$3.49B
1주 성능:
+3.56%
1개월 성능:
+4.76%
6개월 성능:
+4.88%
1년 성능:
+25.90%
1일 변동 폭
$18.80
$19.01
1주일 범위
$18.54
$19.10
52주 변동 폭
$12.99
$19.10
다케다약품공업 ADR Stock (TAK) Company Profile
명칭
Takeda Pharmaceutical Co Adr
전화
-
주소
-
Compare TAK vs TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
18.91 | 58.31B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
38.98 | 43.22B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.28 | 40.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.40 | 30.15B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
494.63 | 21.32B | 3.17B | 1.29B | 1.01B | 27.09 |
다케다약품공업 ADR Stock (TAK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-08 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2026-01-13 | 재개 | Morgan Stanley | Overweight |
| 2025-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-07-19 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-10-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-01 | 개시 | Cowen | Market Perform |
| 2019-08-15 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
모두보기
다케다약품공업 ADR 주식(TAK)의 최신 뉴스
Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider - GlobeNewswire Inc.
Takeda stock advances after U.S. FDA clears MIMRYLO cancer drug - AD HOC NEWS
Protagonist Therapeutics receives FDA approval for polycythemia vera drug - Investing.com
Teva Pharma Industries Ltd ADR (TEVA) Peer Comparison – Compare with Others - valueresearchonline.com
Takeda Pharmaceutical Co Ltd (ADR) (TAK) News, Articles, Events & Latest Updates - Stocktwits
Takeda (NYSE:TAK) Climbs Into Focus On Sleep Disorder Milestone - Kalkine Media
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history - au.finance.yahoo.com
Takeda (TAK) Q1 2026 Earnings Call Transcript - theglobeandmail.com
US FDA approves Takeda’s sleep disorder pill By Reuters - Investing.com
Takeda Pharmaceutical (TAK) Slips 0.93% to $17.09 as Defensive Sector Shows Mixed ToneBlock Trade Flow - vinanet.vn
Corporate Lobbying Dashboard - Quiver Quantitative
Murata ADR Surges 15%, SoftBank Group Jumps 7% as Semiconductor, Tech Stocks See Short-Covering - finance.biggo.com
Takeda Pharmaceutical (TAK) Gains 2.5%; Approaches Key Resistance LevelBPI Bull Correction - vinanet.vn
Teva Pharmaceutical Industries Limited (TEVA) stock price, news, quote and history - Yahoo Finance UK
TAK: Takeda Pharmaceutical Co Ltd (ADR) Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Takeda invests $30M to build Indonesian plasma ecosystem - grafa.com
Form 144 Takeda Pharmaceutical Company Limited For: 13 July By Investing.com - Investing.com Canada
6 High-Yield International Dividend Stocks Analysts Love - Forbes
ETFs Investing in Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stocks - TradingView
TAKTakeda Pharmaceutical Co ADR Latest SEC Filings - Finviz
India Celiac Disease Treatment Market Size & Outlook, 2033 - grandviewresearch.com
0A87 Forecast — Price Target — Prediction for 2027 - TradingView
TAK-755 from Takeda Pharmaceutical Co.enzyme replacement for a rare bleeding disorder - Ad-hoc-news.de
TKDA Forecast — Price Target — Prediction for 2027 - TradingView
Takeda Pharmaceutical Co. Ltd. Sponsored ADR Actuals & Estimates (LS:A1CWZF) - TradingView
A1CWZF Forecast — Price Target — Prediction for 2027 - TradingView
TAK/N Forecast — Price Target — Prediction for 2027 - TradingView
Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR - TradingView
Takeda Pharmaceutical Co. Ltd. Sponsored ADR Actuals & Estimates (GETTEX:TKDA) - TradingView
Takeda Pharmaceutical StockAnalyst sentiment and chart picture on Thursday - AD HOC NEWS
Why Takeda’s Entyvio subcutaneous dose is changing quiet routines for gut patients - AD HOC NEWS
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data - Sahm
Takeda Pharmaceutical Co Ltd (TAK) Stock Price, Trades & News - GuruFocus
Takeda zasocitinib beats deucravacitinib in Phase 3 psoriasis trial - grafa.com
다케다약품공업 ADR (TAK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.54%
자본화:
|
볼륨(24시간):